前淘宝总裁，要IPO敲钟了

Core Insights - Mirxes Holding Company Limited (Mirxes Group) is nearing its IPO after a lengthy process involving four submissions, with the listing hearing successfully passed on May 12 [1] - The company specializes in RNA technology, focusing on early disease detection diagnostic solutions globally [1] - The largest shareholder is Sun Tongyu, a prominent figure in Alibaba, adding a layer of intrigue to the company's profile [1] Company Overview - Founded in 2014 by three PhDs, Mirxes Group has concentrated on developing cancer test kits since its inception [1] - The company is recognized as a provider of effective, non-invasive, and affordable blood-based miRNA test kits for early cancer and disease detection, according to Frost & Sullivan [1] Product Development - As of April 27, 2025, Mirxes Group has established a comprehensive product matrix, including one core product (GASTROClearTM), two commercialized products (LUNGClearTM and FortitudeTM), and six candidates in preclinical stages [2] - GASTROClearTM is particularly notable as it is the first and only approved molecular diagnostic IVD product for gastric cancer screening globally, having received certification from Singapore's Health Sciences Authority in May 2019 [3] Financial Performance - The company reported revenues of approximately $17.76 million, $24.19 million, and $20.28 million for the years 2022, 2023, and 2024, respectively, with corresponding gross profits of about $9.33 million, $13.58 million, and $8.89 million [3] - Losses for the same periods were approximately $56.20 million, $69.57 million, and $92.21 million [3] Investment and Valuation - Mirxes Group has attracted significant investment from various notable capital firms, including Gao Rong Capital and Nuo Hui Capital, with a post-investment valuation of $600 million following a Series D funding round in July 2023 [3][4] - The company’s major shareholders include Sun Tongyu (22.03%), Dr. Zhu Xingfen (14.11%), and Dr. Zhou Lihan (8.12%), among others [5] IPO Utilization - The primary use of funds raised from the IPO will be for the research and development, regulatory filing, and production of the core product GASTROClearTM, as well as funding ongoing and planned R&D projects [7] - The company aims to enhance and integrate its "end-to-end" capabilities through the raised capital [7] Future Outlook - With the successful passage of the listing hearing and strong backing from capital and technological innovation, Mirxes Group's future development appears promising in the early disease detection sector [8]